135 related articles for article (PubMed ID: 27078579)
1. Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Liu Q; Chen X; Chen W; Yuan X; Su H; Shen J; Xu Y
J Med Chem; 2016 May; 59(10):5115-20. PubMed ID: 27078579
[TBL] [Abstract][Full Text] [Related]
2. Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.
Guibbal F; Bénard S; Patché J; Meneyrol V; Couprie J; Yong-Sang J; Meilhac O; Jestin E
Bioorg Med Chem Lett; 2018 Feb; 28(4):787-792. PubMed ID: 29336874
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
Chen X; Wang K; Xu W; Ma Q; Chen M; Du L; Mo M; Wang Y; Shen J
J Med Chem; 2016 Mar; 59(6):2674-87. PubMed ID: 26927682
[TBL] [Abstract][Full Text] [Related]
4. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
[TBL] [Abstract][Full Text] [Related]
5. Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Woolford AJ; Pero JE; Aravapalli S; Berdini V; Coyle JE; Day PJ; Dodson AM; Grondin P; Holding FP; Lee LY; Li P; Manas ES; Marino J; Martin AC; McCleland BW; McMenamin RL; Murray CW; Neipp CE; Page LW; Patel VK; Potvain F; Rich S; Rivero RA; Smith K; Somers DO; Trottet L; Velagaleti R; Williams G; Xie R
J Med Chem; 2016 Jun; 59(11):5356-67. PubMed ID: 27167608
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of imidazole and triazole derivatives as Lp-PLA₂ inhibitors and the unexpected discovery of highly potent quaternary ammonium salts.
Wang K; Xu W; Liu Y; Zhang W; Wang W; Shen J; Wang Y
Bioorg Med Chem Lett; 2013 Mar; 23(5):1187-92. PubMed ID: 23385210
[TBL] [Abstract][Full Text] [Related]
7. Impact of tyrosine nitration at positions Tyr307 and Tyr335 on structural dynamics of Lipoprotein-associated phospholipase A
Gurung AB; Bhattacharjee A
Int J Biol Macromol; 2018 Feb; 107(Pt B):1956-1964. PubMed ID: 29051098
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2: The story continues.
Huang F; Wang K; Shen J
Med Res Rev; 2020 Jan; 40(1):79-134. PubMed ID: 31140638
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Liu Q; Huang F; Yuan X; Wang K; Zou Y; Shen J; Xu Y
J Med Chem; 2017 Dec; 60(24):10231-10244. PubMed ID: 29193967
[TBL] [Abstract][Full Text] [Related]
10. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
Tellis CC; Tselepis AD
Biochim Biophys Acta; 2009 May; 1791(5):327-38. PubMed ID: 19272461
[TBL] [Abstract][Full Text] [Related]
11. Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.
Huang F; Hu H; Wang K; Peng C; Xu W; Zhang Y; Gao J; Liu Y; Zhou H; Huang R; Li M; Shen J; Xu Y
J Med Chem; 2020 Jul; 63(13):7052-7065. PubMed ID: 32459096
[TBL] [Abstract][Full Text] [Related]
12. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A
Mouchlis VD; Morisseau C; Hammock BD; Li S; McCammon JA; Dennis EA
Bioorg Med Chem; 2016 Oct; 24(20):4801-4811. PubMed ID: 27320659
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Chen X; Xu W; Wang K; Mo M; Zhang W; Du L; Yuan X; Xu Y; Wang Y; Shen J
J Med Chem; 2015 Nov; 58(21):8529-41. PubMed ID: 26479945
[TBL] [Abstract][Full Text] [Related]
14. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.
Fenning RS; Burgert ME; Hamamdzic D; Peyster EG; Mohler ER; Kangovi S; Jucker BM; Lenhard SC; Macphee CH; Wilensky RL
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672369
[TBL] [Abstract][Full Text] [Related]
15. Impact of a non-synonymous Q281R polymorphism on structure of human Lipoprotein-Associated Phospholipase A
Gurung AB; Bhattacharjee A
J Cell Biochem; 2018 Aug; 119(8):7009-7021. PubMed ID: 29737567
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2.
McConnell JP; Hoefner DM
Clin Lab Med; 2006 Sep; 26(3):679-97, vii. PubMed ID: 16938590
[TBL] [Abstract][Full Text] [Related]
17. Met117 oxidation leads to enhanced flexibility of cardiovascular biomarker- lipoprotein- associated phospholipase A
Gurung AB; Bhattacharjee A
Int J Biol Macromol; 2018 Jun; 112():831-840. PubMed ID: 29427679
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Wilensky RL; Macphee CH
Curr Opin Lipidol; 2009 Oct; 20(5):415-20. PubMed ID: 19667981
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.
Li D; Zhao L; Yu J; Zhang W; Du R; Liu X; Liu Y; Chen Y; Zeng R; Cao Y; Zeng Z; Zhao Z; Wu J
Clin Chim Acta; 2017 Feb; 465():22-29. PubMed ID: 27956130
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Packard CJ
Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]